Table 2.
Randomized trials with alternative design
| Reference | No. of patients* | Age (y) | Reason for classification as group 2 | QoL† |
|---|---|---|---|---|
| Conventional chemotherapy | ||||
| 39 | 965 | 16-60 | No observation-only arm | No |
| 43 | 598 | ≤64 | More consolidation vs less + maintenance | No |
| 26 | 325 | Any | No strategy used to balance groups for previous therapies‡ | No |
| 32 | 150 | Any | No observation-only arm | No |
| 58 | 208 | ≤50 | No strategy used to balance groups for previous therapies‡ | No |
| 33 | 41 | ≤65 | No strategy used to balance groups for previous therapies‡ | No |
| 59 | NA | ≤21 | No strategy used to balance groups for previous therapies‡ | No |
| 47 | 131 | ≥16 | No observation-only arm | No |
| 28 | 170 | ≤65 | Maintenance arm received no consolidation | No |
| 27 | NA | >16 | Maintenance arm received no consolidation | No |
| 54 | 82 | ≥51 | No strategy used to balance groups for previous therapies‡ | No |
| 44 | 47 | 50-70 | No strategy used to balance groups for previous therapies‡ | No |
| 35 | 248 | NA | No observation-only arm | No |
| 34 | 48 | NA | No observation-only arm | No |
| 51 | 275 | Any | More consolidation vs less + maintenance | No |
| Hypomethylating agents | ||||
| 46 | 214 | ≥61 | No strategy used to balance groups for previous therapies‡ | No |
| 29 | 727 | ≥60 | No strategy used to balance groups for previous therapies‡ | No |
| 60 | 176 | NA | No observation-only arm | No |
| 24 | 45 | ≥18 | No observation-only arm | No |
| Immunotherapy (alone or combined with chemotherapy) | ||||
| 37,38 | 214 | <60 | No strategy used to balance groups for previous therapies‡ | No |
| 50§ | 169 | ≤60 | No strategy used to balance groups for previous therapies‡ | No |
| 41 | 289 | ≤21 | No strategy used to balance groups for previous therapies‡ | No |
| 25 | 261 | ≥18 | No strategy used to balance groups for previous therapies‡ | No |
| 31 | 362 | >55 | No strategy used to balance groups for previous therapies‡ | No |
| 23 | 78 | <50 | Following auto-SCT | No |
| 45 | 91 | ≥15 | No strategy used to balance groups for previous therapies‡ | No |
| 48 | 66 | ≥15 | No observation-only arm | No |
| 57 | 215 | ≥15 | No strategy used to balance groups for previous therapies‡ | No |
| 40 | 35 | ≤84 | No observation-only arm | No |
| 49 | 97 | >15 | No strategy used to balance groups for previous therapies‡ | No |
| 30 | 47 | Any | No observation-only arm | No |
| 56 | 15 | 18-65 | No strategy used to balance groups for previous therapies‡ | No |
| Small molecules | ||||
| 42 | 144 | Any | No strategy used to balance groups for previous therapies‡ | No |
| 55 | 717 | ≤60 | No strategy used to balance groups for previous therapies‡ | No |
| 52 | 267 | ≤60 | No strategy used to balance groups for previous therapies‡ | No |
| 53 | 197 | >60 | No strategy used to balance groups for previous therapies‡ | No |
| 36 | 111 | ≥15 | No strategy used to balance groups for previous therapies‡ | No |
*
Randomly assigned between maintenance arms.
†
QoL was formally assessed.
‡
See text for details.
§
This study was terminated early.